Quantification of cibenzoline and its imidazole metabolite by high-performance liquid chromatography in human serum. 1990

V Kühlkamp, and F Schmid, and K M Ress, and B K Krämer, and F Mayer, and H M Liebich, and T Risler, and L Seipel
Medizinische Klinik Abteilung III, Tübingen, F.R.G.

UI MeSH Term Description Entries
D007093 Imidazoles Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000889 Anti-Arrhythmia Agents Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. Anti-Arrhythmia Agent,Anti-Arrhythmia Drug,Anti-Arrhythmic,Antiarrhythmia Agent,Antiarrhythmia Drug,Antiarrhythmic Drug,Antifibrillatory Agent,Antifibrillatory Agents,Cardiac Depressant,Cardiac Depressants,Myocardial Depressant,Myocardial Depressants,Anti-Arrhythmia Drugs,Anti-Arrhythmics,Antiarrhythmia Agents,Antiarrhythmia Drugs,Antiarrhythmic Drugs,Agent, Anti-Arrhythmia,Agent, Antiarrhythmia,Agent, Antifibrillatory,Agents, Anti-Arrhythmia,Agents, Antiarrhythmia,Agents, Antifibrillatory,Anti Arrhythmia Agent,Anti Arrhythmia Agents,Anti Arrhythmia Drug,Anti Arrhythmia Drugs,Anti Arrhythmic,Anti Arrhythmics,Depressant, Cardiac,Depressant, Myocardial,Depressants, Cardiac,Depressants, Myocardial,Drug, Anti-Arrhythmia,Drug, Antiarrhythmia,Drug, Antiarrhythmic,Drugs, Anti-Arrhythmia,Drugs, Antiarrhythmia,Drugs, Antiarrhythmic
D001281 Atrial Fibrillation Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation. Auricular Fibrillation,Familial Atrial Fibrillation,Paroxysmal Atrial Fibrillation,Persistent Atrial Fibrillation,Atrial Fibrillation, Familial,Atrial Fibrillation, Paroxysmal,Atrial Fibrillation, Persistent,Atrial Fibrillations,Atrial Fibrillations, Familial,Atrial Fibrillations, Paroxysmal,Atrial Fibrillations, Persistent,Auricular Fibrillations,Familial Atrial Fibrillations,Fibrillation, Atrial,Fibrillation, Auricular,Fibrillation, Familial Atrial,Fibrillation, Paroxysmal Atrial,Fibrillation, Persistent Atrial,Fibrillations, Atrial,Fibrillations, Auricular,Fibrillations, Familial Atrial,Fibrillations, Paroxysmal Atrial,Fibrillations, Persistent Atrial,Paroxysmal Atrial Fibrillations,Persistent Atrial Fibrillations

Related Publications

V Kühlkamp, and F Schmid, and K M Ress, and B K Krämer, and F Mayer, and H M Liebich, and T Risler, and L Seipel
December 1983, Journal of chromatography,
V Kühlkamp, and F Schmid, and K M Ress, and B K Krämer, and F Mayer, and H M Liebich, and T Risler, and L Seipel
January 2006, Arzneimittel-Forschung,
V Kühlkamp, and F Schmid, and K M Ress, and B K Krämer, and F Mayer, and H M Liebich, and T Risler, and L Seipel
April 1996, Therapeutic drug monitoring,
V Kühlkamp, and F Schmid, and K M Ress, and B K Krämer, and F Mayer, and H M Liebich, and T Risler, and L Seipel
June 1984, Journal of chromatography,
V Kühlkamp, and F Schmid, and K M Ress, and B K Krämer, and F Mayer, and H M Liebich, and T Risler, and L Seipel
June 2008, Therapeutic drug monitoring,
V Kühlkamp, and F Schmid, and K M Ress, and B K Krämer, and F Mayer, and H M Liebich, and T Risler, and L Seipel
June 1979, Clinical biochemistry,
V Kühlkamp, and F Schmid, and K M Ress, and B K Krämer, and F Mayer, and H M Liebich, and T Risler, and L Seipel
September 1988, Journal of chromatography,
V Kühlkamp, and F Schmid, and K M Ress, and B K Krämer, and F Mayer, and H M Liebich, and T Risler, and L Seipel
August 1987, Journal of chromatography,
V Kühlkamp, and F Schmid, and K M Ress, and B K Krämer, and F Mayer, and H M Liebich, and T Risler, and L Seipel
January 1989, Yao xue xue bao = Acta pharmaceutica Sinica,
V Kühlkamp, and F Schmid, and K M Ress, and B K Krämer, and F Mayer, and H M Liebich, and T Risler, and L Seipel
October 1983, Journal of chromatography,
Copied contents to your clipboard!